{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T06:32:01Z","timestamp":1768977121829,"version":"3.49.0"},"reference-count":69,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AstraZeneca-MSD Alliance"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>A group of experts of different specialties involved in the care of prostate cancer (PCa) patients participated in the ENFOCA2 project, promoted by the Spanish Oncology Genitourinary Group (SOGUG), with the aim to review, discuss, and summarize current relevant aspects related to screening, diagnosis, imaging, risk-based approach, and molecular characterization of PCa. A multidisciplinary team (MDT) approach is essential to ensure that patients receive evidence-based care, promoting shared decision-making, and tailoring treatment to the patient\u2019s unique values and preferences. Population-based screening based on risk-stratified algorithms is needed to overcome the limitations of opportunistic screening for detecting clinically significant PCa. Next-generation imaging (NGI) methods, such as prostate-specific membrane antigen (PSMA) PET\/CT alone or combined with multiparametric MRI (mpMRI), have a promising role in different scenarios of the diagnostic process due to their high sensitivity. The diagnostic yield of mpMRI should be improved, especially for assessing extraprostatic extension. The use of specific molecular probes as imaging markers for MRI could improve the staging of metastatic disease. Protocols for germline testing developed by international societies, such as the European Association of Urology (EAU) and the National Comprehensive Cancer Network (NCCN), should be adapted at local levels, with BRCA1\/2, ATM, PALB2, CHEK2, MLH1, MSH2, MSH6, PMS2, EPCAM, and HOXB13 as the genes to be investigated. Genomic classifier tools help identifying aggressiveness of cancers and aid in personalized treatment decision-making. Joint efforts of multidisciplinary physicians are crucial to improve health outcomes for patients with PCa across the spectrum of this disease.<\/jats:p>","DOI":"10.3390\/curroncol33010061","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T17:20:42Z","timestamp":1768929642000},"page":"61","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SOGUG Multidisciplinary Expert Panel Consensus on Updated Diagnosis and Characterization of Prostate Cancer Patients"],"prefix":"10.3390","volume":"33","author":[{"given":"Enrique","family":"Gallardo","sequence":"first","affiliation":[{"name":"Department of Oncology, Parc Taul\u00ed Hospital Universitari, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Universitat Aut\u00f2noma de Barcelona, 08202 Sabadell, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"G\u00f3mez-de-Iturriaga","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Cruces, Vizcaya, Biobizkaia Health Research Institute, Basque Country University (UPV\/EHU), 48940 Santsoena, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Mu\u00f1oz-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Department of Urology, Parc Taul\u00ed Hospital Universitari, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Universitat Aut\u00f2noma de Barcelona, 08202 Sabadell, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0733-3276","authenticated-orcid":false,"given":"Isabel","family":"Chirivella-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Servicio Oncolog\u00eda M\u00e9dica, Hospital Cl\u00ednico Universitario, INCLIVA, Universidad de Valencia, 46010 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3143-3143","authenticated-orcid":false,"given":"Enrique","family":"Gonz\u00e1lez-Billababeita","sequence":"additional","affiliation":[{"name":"Hospital General Universitario 12 de Octubre, 28041 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Mart\u00ednez-Ballesteros","sequence":"additional","affiliation":[{"name":"Hospital Universitario Puerta de Hierro-Majadahonda, 28222 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jos\u00e9","family":"M\u00e9ndez-Vidal","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Maimonides Institute for Biomedical Research of C\u00f3rdoba (IMIBIC), Hospital Universitario Reina Sof\u00eda (HURS), 14004 C\u00f3rdoba, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6030-4266","authenticated-orcid":false,"given":"Mercedes","family":"Mitjavila-Casanovas","sequence":"additional","affiliation":[{"name":"JS\u00ba Medicina Nuclear, Hospital Universitario Puerta de Hierro-Majadahonda, 28222 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Pelechano G\u00f3mez","sequence":"additional","affiliation":[{"name":"Servicio de Radiolog\u00eda, Fundaci\u00f3n Instituto Valenciano de Oncolog\u00eda (IVO), 46009 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6570-009X","authenticated-orcid":false,"given":"Ar\u00e1nzazu","family":"Gonz\u00e1lez-del-Alba","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario Puerta de Hierro-Majadahonda, 28222 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4077-0507","authenticated-orcid":false,"given":"Fernando","family":"L\u00f3pez-Campos","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department, Hospital Universitario Ram\u00f3n y Cajal, Madrid, Genesis Care Hospital Vithas La Milagrosa, 28010 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s11523-022-00925-7","article-title":"Addressing challenges and controversies in the management of prostate cancer with multidisciplinary teams","volume":"17","author":"Shore","year":"2022","journal-title":"Target. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: Planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/JU.0000000000001698","article-title":"A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with 18F-DCFPyL in prostate cancer patients (OSPREY)","volume":"206","author":"Pienta","year":"2021","journal-title":"J. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.euf.2016.11.002","article-title":"68Ga-Labeled prostate-specific membrane antigen ligand positron emission tomography\/computed tomography for prostate cancer: A systematic review and meta-analysis","volume":"4","author":"Picchio","year":"2018","journal-title":"Eur. Urol. Focus"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","article-title":"Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: A systematic review and meta-analysis","volume":"77","author":"Perera","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.18.00358","article-title":"PROREPAIR-B: A prospective cohort study of the impact of germline dna repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer","volume":"37","author":"Castro","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1200\/JCO.2022.40.6_suppl.223","article-title":"An AI-derived digital pathology-based biomarker to predict the benefit of androgen deprivation therapy in localized prostate cancer with validation in NRG\/RTOG 9408","volume":"40","author":"Spratt","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2010.10.029","article-title":"The requirements of a specialist Prostate Cancer Unit: A discussion paper from the European School of Oncology","volume":"47","author":"Valdagni","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.critrevonc.2015.05.014","article-title":"Prostate Cancer Unit Initiative in Europe: A position paper by the European School of Oncology","volume":"95","author":"Valdagni","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.eururo.2019.01.033","article-title":"The European Prostate Cancer Centres of Excellence: A novel proposal from the European Association of Urology Prostate Cancer Centre Consensus Meeting","volume":"76","author":"Wirth","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_16","unstructured":"(2024, June 13). What Is Value-Based Healthcare? NEJM Catalyst. Available online: https:\/\/catalyst.nejm.org\/doi\/full\/10.1056\/CAT.17.0558."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.eururo.2014.08.075","article-title":"Defining a standard set of patient-centered outcomes for men with localized prostate cancer","volume":"67","author":"Martin","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/cncr.30474","article-title":"Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years","volume":"123","author":"Pinsky","year":"2017","journal-title":"Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A 16-yr follow-up of the European Randomized study of Screening for Prostate Cancer","volume":"76","author":"Hugosson","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.euros.2023.05.011","article-title":"How to follow the new EU Council recommendation and improve prostate cancer early detection: The Prostaforum 2022 declaration","volume":"53","author":"Babjuk","year":"2023","journal-title":"Eur. Urol. Open Sci."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"US Preventive Services Task Force, Grossman, D.C., Curry, S.J., Owens, D.K., Bibbins-Domingo, K., Caughey, A.B., Davidson, K.W., Doubeni, C.A., Ebell, M., and Epling, J.W. (2018). Screening for prostate cancer: US Preventive Services Task Force Recommendation Statement. JAMA, 319, 1901\u20131913.","DOI":"10.1001\/jama.2018.3710"},{"key":"ref_22","unstructured":"American Academy of Family Physicians (AAFP) (2024, June 13). Prostate Cancer Screening. Available online: https:\/\/www.aafp.org\/family-physician\/patient-care\/clinical-recommendations\/all-clinical-recommendations\/prostate-cancer.html."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1503\/cmaj.140703","article-title":"Canadian Task Force on Preventive Health Care Recommendations on screening for prostate cancer with the prostate-specific antigen test","volume":"186","author":"Bell","year":"2014","journal-title":"CMAJ"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"761","DOI":"10.7326\/0003-4819-158-10-201305210-00633","article-title":"Screening for prostate cancer: A guidance statement from the Clinical Guidelines Committee of the American College of Physicians","volume":"158","author":"Qaseem","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/JU.0000000000003491","article-title":"Early detection of prostate cancer: AUA\/SUO Guideline Part I: Prostate Cancer Screening","volume":"210","author":"Wei","year":"2023","journal-title":"J. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_27","unstructured":"Hogenhout, R. (2026, January 15). What Is the Best Method of Risk Stratification Before Biopsy? Algorithm for Further Risk Stratification Ready to Be Tested in Pilots in Europe. Eur. Urol. Today. March 2023\u2013Congress edition, 14. Available online: https:\/\/online.flippingbook.com\/view\/210913538\/14\/."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.euo.2021.06.006","article-title":"A European model for an organised risk-stratified early detection programme for prostate cancer","volume":"4","author":"Hogenhout","year":"2021","journal-title":"Eur. Urol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41585-022-00638-6","article-title":"Serum PSA-based early detection of prostate cancer in Europe and globally: Past, present and future","volume":"19","author":"Albreht","year":"2022","journal-title":"Nat. Rev. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.euf.2022.06.008","article-title":"Designing and implementing a population-based organised prostate cancer testing programme","volume":"8","author":"Alterbeck","year":"2022","journal-title":"Eur. Urol. Focus."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/bco2.230","article-title":"A risk-organised model for clinically significant prostate cancer early detection","volume":"4","author":"Morote","year":"2023","journal-title":"BJUI Compass"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): A paired validating confirmatory study","volume":"389","author":"Ahmed","year":"2017","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.eururo.2015.08.052","article-title":"PI-RADS Prostate Imaging\u2014Reporting and Data System: 2015, Version 2","volume":"69","author":"Weinreb","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/MOU.0b013e32835ad3ee","article-title":"MRI-ultrasound fusion for guidance of targeted prostate biopsy","volume":"23","author":"Marks","year":"2013","journal-title":"Curr. Opin. Urol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13244-023-01422-9","article-title":"Imaging features of the PI-RADS for predicting extraprostatic extension of prostate cancer: Systematic review and meta-analysis","volume":"14","author":"Choi","year":"2023","journal-title":"Insights Imaging"},{"key":"ref_36","first-page":"741","article-title":"The diagnostic imaging of bone metastases","volume":"111","author":"Heindel","year":"2014","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1200\/JCO.2006.09.2940","article-title":"Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: Diagnostic and cost-effectiveness and comparison with current detection strategies","volume":"25","author":"Lecouvet","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"72","DOI":"10.4103\/iju.IJU_238_20","article-title":"Comparison of whole-body bone scintigraphy with axial skeleton magnetic resonance imaging in the skeletal evaluation of carcinoma prostate","volume":"37","author":"Venkatachalapathy","year":"2021","journal-title":"Indian. J. Urol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"893193","DOI":"10.1155\/2012\/893193","article-title":"Modern detection of prostate cancer\u2019s bone metastasis: Is the bone scan era over?","volume":"2012","author":"Tombal","year":"2012","journal-title":"Adv. Urol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.19.02757","article-title":"Optimum imaging strategies for advanced prostate cancer: ASCO Guideline","volume":"38","author":"Trabulsi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1148\/radiol.2019181931","article-title":"Imaging diagnosis and follow-up of advanced prostate cancer: Clinical perspectives and state of the art","volume":"292","author":"Tunariu","year":"2019","journal-title":"Radiology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eururo.2016.05.033","article-title":"METastasis Reporting and Data System for Prostate Cancer: Practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer","volume":"71","author":"Padhani","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.eururo.2023.03.001","article-title":"Head-to-head comparison of the diagnostic accuracy of prostate-specific membrane antigen positron emission tomography and conventional imaging modalities for initial staging of intermediate- to high-risk prostate cancer: A systematic review and meta-analysis","volume":"84","author":"Chow","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","article-title":"The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): A prospective multicentre study","volume":"80","author":"Emmett","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.eururo.2015.07.029","article-title":"Accuracy of magnetic resonance imaging for local staging of prostate cancer: A diagnostic meta-analysis","volume":"70","author":"Hamoen","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"847.e9","DOI":"10.1016\/j.urolonc.2020.04.011","article-title":"External validation of the Briganti nomogram predicting lymph node invasion in patients with intermediate and high-risk prostate cancer diagnosed with magnetic resonance imaging-targeted and systematic biopsies: A European multicenter study","volume":"38","author":"Diamand","year":"2020","journal-title":"Urol. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euo.2021.08.001","article-title":"Can negative prostate-specific membrane antigen positron emission tomography\/computed tomography avoid the need for pelvic lymph node dissection in newly diagnosed prostate cancer patients? A systematic review and meta-analysis with backup histology as reference standard","volume":"5","author":"Stabile","year":"2022","journal-title":"Eur. Urol. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"467","DOI":"10.23736\/S2724-6051.24.05736-7","article-title":"PSMA PET for lymph node staging in intermediate and high-risk prostate cancer patients undergoing robotic assisted radical prostatectomy","volume":"76","author":"Spena","year":"2024","journal-title":"Minerva Urol. Nephrol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s00259-020-05058-5","article-title":"Improved oncological outcome after radical prostatectomy in patients staged with 68Ga-PSMA-11 PET: A single-center retrospective cohort comparison","volume":"48","author":"Ferraro","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Kader, A., Brangsch, J., Kaufmann, J.O., Zhao, J., Mangarova, D.B., Moeckel, J., Adams, L.C., Sack, I., Taupitz, M., and Hamm, B. (2020). Molecular MR Imaging of Prostate Cancer. Biomedicines, 9.","DOI":"10.3390\/biomedicines9010001"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1200\/JCO.20.00046","article-title":"Implementation of germline testing for prostate cancer: Philadelphia Prostate Cancer Consensus Conference 2019","volume":"38","author":"Giri","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"236","DOI":"10.6004\/jnccn.2023.0014","article-title":"NCCN Guidelines\u00ae insights: Prostate cancer early detection, Version 1.2023","volume":"21","author":"Moses","year":"2023","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/bjc.2012.146","article-title":"Germline BRCA1 mutations increase prostate cancer risk","volume":"106","author":"Leongamornlert","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Shah, S., Rachmat, R., Enyioma, S., Ghose, A., Revythis, A., and Boussios, S. (2021). BRCA mutations in prostate cancer: Assessment, implications and treatment considerations. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222312628"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"9","DOI":"10.15537\/smj.2020.1.24759","article-title":"BRCA2 gene mutation and prostate cancer risk. Comprehensive review and update","volume":"41","author":"Junejo","year":"2020","journal-title":"Saudi Med J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1634\/theoncologist.2015-0336","article-title":"The PROFILE Feasibility Study: Targeted screening of men with a family history of prostate cancer","volume":"21","author":"Castro","year":"2016","journal-title":"Oncologist"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/JU.0000000000000137","article-title":"Bringing prostate cancer germline genetics into clinical practice","volume":"202","author":"Das","year":"2019","journal-title":"J. Urol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"Cancer Genome Atlas Research Network. The Molecular Taxonomy of Primary Prostate Cancer","volume":"163","author":"Abeshouse","year":"2015","journal-title":"Cell"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2020.11.021","article-title":"A systematic review of the evidence for the decipher genomic classifier in prostate cancer","volume":"79","author":"Jairath","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1200\/JCO.19.02267","article-title":"17-Gene genomic prostate score test results in the Canary Prostate Active Surveillance Study (PASS) cohort","volume":"38","author":"Lin","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ijrobp.2021.09.034","article-title":"The Clinical Cell-Cycle Risk (CCR) score is associated with metastasis after radiation therapy and provides guidance on when to Forgo combined androgen deprivation therapy with dose-escalated radiation","volume":"113","author":"Tward","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1001\/jamaoncol.2017.0751","article-title":"Associations of luminal and basal subtyping of prostate cancer with prognosis and response to androgen deprivation therapy","volume":"3","author":"Zhao","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1200\/JCO.2020.38.6_suppl.162","article-title":"Luminal B subtype as a predictive biomarker of docetaxel benefit for newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A correlative study of E3805 CHAARTED","volume":"38","author":"Hamid","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"LBA16","DOI":"10.1200\/JCO.2023.41.6_suppl.LBA16","article-title":"Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC)","volume":"41","author":"Clarke","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.1200\/JCO.2023.41.16_suppl.5004","article-title":"TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations","volume":"41","author":"Fizazi","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): A randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3390\/clinpract14020039","article-title":"Tissue-based genomic testing in prostate cancer: 10-year analysis of national trends on the use of Prolaris, Decipher, ProMark, and Oncotype DX","volume":"14","author":"Bologna","year":"2024","journal-title":"Clin. Pr."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/1\/61\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T17:31:18Z","timestamp":1768930278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/1\/61"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["curroncol33010061"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33010061","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]}}}